TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06613438: Safety and Effectiveness of eGERD Device to Reduce Gastroesophageal Reflux Disease (GERD) Symptoms

Sponsor: Gerd Care Medical Ltd · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 84 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$896,400

Rescue Site Savings

+$597,600

Unlock Full NCT06613438 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06613438 Rescue Dossier →